Skip to search formSkip to main contentSkip to account menu

pomalidomide

Known as: 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide, 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione, 4-Aminothalidomide 
An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact… 
National Institutes of Health

Related topics

Related topics

13 relations
Angiogenesis InhibitionNCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisThalidomide

Broader (2)

Angiogenesis InhibitorsImmunologic Factors

Narrower (4)

CC-4047ImnovidPomalystactimid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effective therapeutics for… 
Review
2017
Review
2017
Novel Therapies in Light Chain Amyloidosis
2016
2016
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
8005Background: Isatuximab (ISA) is a humanized anti-CD38 monoclonal antibody with multiple modes of action for killing tumor… 
2016
2016
A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma
Introduction:CD38 is a type II transmembrane glycoprotein widely expressed in many hematological malignancies including multiple… 
2016
2016
Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis.
Amyloidosis is a condition in which misfolded proteins form insoluble deposits in the extracellular space of various tissues and… 
Review
2013
Review
2013
Diagnosis and therapy of multiple myeloma
Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel… 
Highly Cited
2012
Highly Cited
2012
Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding
Highly Cited
2011
Highly Cited
2011
Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma
Background Pomalidomide is a distinct IMiD® immunomodulatory agent with activity in subjects with relapsed or refractory MM (RRMM… 
Review
2011
Review
2011
Pomalidomide therapy for myeloma
Introduction: The Office of National Statistics (London, UK) has reported 4040 new patients in the year 2007, with an annual age… 
2011
2011
Circulating levels of MCP‐1, sIL‐2R, IL‐15, and IL‐8 predict anemia response to pomalidomide therapy in myelofibrosis
Cytokine‐phenotype associations have recently been described in primary myelofibrosis and increased levels of IL‐8, sIL‐2R, IL‐12… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)